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ABSTRACT
Behçet’s disease (BD) activity is characterised by sustained, over-exuberant immune activation,
yet the underlying mechanisms leading to active BD state are poorly defined. Herein, we show
that the human cathelicidin derived antimicrobial peptide LL37 associates with and directs
plasma extracellular vesicles (EV) to immune cells, thereby leading to enhanced immune activa-
tion aggravating BD pathology. Notably, disease activity was correlated with elevated levels of
circulating LL37 and EV plasma concentration. Stimulation of healthy PBMC with active BD
patient EVs induced heightened IL1β, IFNα, IL6 and IP10 secretion compared to healthy and
inactive BD EVs. Remarkably, when mixed with LL37, healthy plasma-EVs triggered a robust
immune activation replicating the pathology inducing properties of BD EVs. The findings of this
study could be of clinical interest in the management of BD, implicating LL37/EV association as
one of the major contributors of BD pathogenesis.
Abbreviations: BD: Behçet’s disease; EV: extracellular vesicle; BB: binding buffer; AnV: annexin V;
autologEV: autologous extracellular vesicles; alloEV: allogeneic extracellular vesicles
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Behçet’s disease (BD) is a complex multi-organ chronic
inflammatory condition of unknown etiology wherein the
genetic background and environmental factors are thought
to be important contributors for disease pathogenesis.[1–
5] Recent findings suggest that a predominance of Th1/
Th17-type immune polarisations and elevated levels of
associated cytokines correlate with disease activity.[6–9]
In this context, plasmapheresis has been shown to induce
rapid short-term remission suggesting that an unidentified
plasma-associated factor could be a trigger of flare-ups.[10]
Herein, we hypothesised that one such plasma-related
factor contributing to disease activity and severity could
be the circulating extracellular vesicles (EV).
EVs are small vesicles (diameter of 30 nm to 1 µm)
constitutively released from various cell types and are
considered as key players mediating cell-to-cell commu-
nication.[11–13] Accumulating evidence suggests that
plasma EV levels are altered during disease states.[12]
For instance, the number of EVs released from cultured
immune cells increases dramatically upon stimulation
with TNFα or IL1β. Moreover, several apoptosis inducers
contribute to EV secretion.[13–17] In addition, stimula-
tion of RAW 264.7 cells by TLR ligands intensify EV
release.[18] EVs have several roles in immune modula-
tion along with stimulation of coagulation, and modula-
tion of vascular functions.[19–25] In general, their cargo
is loaded with an array of bioactive molecules capable of
regulating target cell behaviour.[23–27] Recent studies
revealed that numbers of circulating EVs were elevated
in several rheumatologic diseases, such as rheumatoid
arthritis, systemic lupus erythematosus, primary
Sjögren’s syndrome, vasculitis and anti-phospholipid
syndrome.[20–31] The implications of elevated EV levels
were not fully understood.
Since inflammation, endothelial dysfunction, and
thrombotic tendency are collectively regarded as cardi-
nal features of BD, we speculated that the levels and
source of EVs along with their cargo might influence the
course of BD in terms of disease activity and severity.
In this study, we report that circulating EV numbers
correlate with BD severity. Furthermore, we show that
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Consecutive patients, who were regularly examined at the
Department of Rheumatology and had an established
diagnosis of BD (according to the criteria of the
International Study Group for Behçet’s Disease [32]),
were referred for the study after they had their last clinical
evaluation to determine clinical disease status (see
Table 1). For this study, plasma of 72 BD patients (active;
n = 35, inactive; n = 37) and 22 healthy control indivi-
duals were included. Patients having active disease was
defined by the presence of two and more clinical char-
acteristics, such as oral ulcers, genital ulcers, papulopust-
ular or pseudo-follicular cutaneous lesions, active
vascular disease and active ocular involvement. The
patients who had no symptoms related with BD at the
time of sampling and receiving steady medication for at
least one month were classified as having an inactive
disease. All patients were further categorised according
to their organ of involvement as (i) mucocutaneous, (ii)
ocular, and (iii) vascular. With regard to the classification
of those patients with inactive disease, patients’ detailed
clinical history was investigated with respect to either
deep vein thrombosis or arterial aneurysm and evidence
for uveitis was sought. Subjects with hypertension, dia-
betes mellitus, renal disease or a previous history of
coronary artery disease or myocardial infarction were
excluded. The healthy control group included 22 indivi-
duals, matched for age and sex. Baseline characteristics of
patients with BD and healthy subjects at inclusion are
summarised in Table 1. The study was approved by the
Institutional Review Board, and all participants provided
their informed consents.
Collection of platelet poor plasma from PBMCs
Fresh blood samples collected into sodium citrate con-
taining vacutainers were centrifuged at 400g for 10 min;
plasma was separated and further centrifuged at 1500g for
10 min to obtain platelet poor plasma (PPP). The PPP
was collected and divided into 1.5ml aliquots, whichwere
snap-frozen in liquid nitrogen and kept at −80°C.
Isolation of EVs by differential centrifugation
EV isolation from PPP was based on the differential cen-
trifugation method.[33] All reagents used throughout the
purification were filtered using 0.2 µm filters and then
centrifuged at 100,000g for two hours. Briefly, PPPs were
thawed centrifuged at 10,000g for 10 min to remove cell
debris. One ml of the supernatant was 35× diluted by PBS-
citrate buffer (10 mM tri-sodium citrate in Ca2+/Mg2+ free
PBS, pH = 7.4) and centrifuged at 100,000g for 1 h (XL90
Beckman ultracentrifuge with a SW28 rotor with
6 × 38.5 ml polyallomer tubes, Beckman Instruments,
Fullerton, CA, USA). The supernatant was discarded, and
the pellet was washed once with PBS-citrate buffer. The
pellet (containing EV fraction) was then dissolved in 150 μl
of buffer, either 1× PBS or binding buffer (BB) (10× BB
was composed of 0.1 M HEPES, 1.4 M NaCl and 25 mM
CaCl2, pH = 7.4).
Purification of EVs by sucrose cushion
Purification of EVs using sucrose cushion was performed
as described elsewhere.[33] The isolated EV pellet, after
the final ultracentrifugation step, was dissolved in 2 ml 1×
PBS. The EVs were then added to 30% (w/v) sucrose
solution in 15 ml ultracentrifuge UC polyallomer tubes
and centrifuged for 2 h at 100,000g. After centrifugation,
3–4 ml of supernatant (including purified EVs) from the
top of the sucrose solution was collected and transferred
into 38.5 ml UC polyallomer tubes. Up to 35 ml 1× PBS
was added onto the solution and centrifuged for 2 h at
100,000g. The EV pellet was collected by using 150 µl 1×
PBS for subsequent analysis.
Characterisation of EVs by western blotting
EVs for western blotting was prepared with RIPA lysis
buffer and protein concentration was determined using
BCA Protein Assay Reagent Kit (Thermo Scientific,
Waltham, MA, USA). An amount of 25 µg of protein
was loaded and separated by SDS-polyacrylamide gel
electrophoresis, transferred to PVDF membrane and
probed with 1:1000 diluted primary antibodies against
Alix (Cell Signaling, Denver, CO, USA) and Grp94 (Cell







Sex (M) 22 37 35
Age (year, mean ± SD) 22 ± 5 22 ± 5 19 ± 6
Disease duration (year,
mean ± SD)
N/A 11 ± 5 8 ± 2
Disease progression
Mucosa N/A 9 16
Vein N/A 12 7
Eye N/A 16 12
Treatment
Colchicine N/A 21 24
Azathioprine N/A 14 11
Cyclophophamide N/A 2 0
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Signaling). Blots were visualised by Amersham Imager
600 (GE, Amersham, UK) after incubating membranes
with 1:10,000 diluted HRP linked secondary antibodies as
anti-mouse IgG (Cell Signaling) and anti-rabbit IgG (Cell
Signaling) for Alix and Grp94 blotting, respectively.
Characterisation of EV markers with bead assay
using flow cytometer
In order to characterise exosomal surface antigens by flow
cytometer, initially, 10 μl carboxyl modified latex beads
(bead diameter: 3.9 µm, Invitrogen, Carlsbad, CA, USA)
were incubated with 10 µg LEAF purified anti-human
CD63 antibody (Biolegend, San Diego, CA, USA) for
30 min at RT and then rotated overnight at RT after
bringing the volume to 500 μl with 1× PBS. Afterwards,
latex bead/anti-CD63 complex were blocked with 5% BSA
(Roche, Basel, Switzerland) containing 1× PBS for 4 h at
RT. Coated and blocked beads were washed twice with 1×
PBS by centrifuging at 3000 g for 10min at RT. The coated
beads were stored in 1× PBS containing 0.1% glycine and
0.1% NaN3 (@pH; 7.2) at a final concentration of 3 × 10-
5 beads μl–1 at 4°C until analysis. Then, 1 μg exosomal
protein containing intact EVs were incubated with 1 μl of
anti-CD63 coated beads in 100 μl FACS Buffer (FB; 1× PBS
containing 5% BSA and 0.05% Tween 20) with gentle
mixing for 30min at RT. EV bound beads were centrifuged
at 3000×g for 10 min and supernatant was removed. Beads
were washed twice with FB. After that exosome/bead com-
plexwere incubatedwith anti-CD9-PE, CD63-PE antibody
(Biolegend) or Annexin V-PE (AnV, Becton Dickenson,
Franklin Lakes, NJ, USA) in FB or in 1× BB, respectively,
for 30 min with gentle mixing at RT. At the end of
incubation period, EV/bead complexes were centrifuged,
washed twice and analysed by BD Accuri C6 (Becton
Dickinson) flow cytometer.
Determination of size distribution of EVs by
dynamic light scattering
Hydrated sizes of EVs isolated from healthy donors and
BD patient plasmas were 100× diluted with 1× PBS and
analysed by dynamic light scatter method on Zetasizer
(Nano ZS, Malvern Instruments, Malwern, UK).
Isolation of exosomes from blood plasma with size
exclusion chromatography
For isolation of exosomes with size exclusion chroma-
tography (SEC), plasma samples (1–1.5 ml) from
Behçet’s patients or healthy donors were diluted up to
2 ml with PBS and centrifuged at 10,000g for 20 min to
get rid of debris and precipitates. The supernatants were
collected, filtered through 0.22 μm filters and subse-
quently loaded on a HiPrep 16/60 Sephacryl S-400 HR
SEC column (GE Healthcare, Uppsala, Sweden) with a
120 ml bed volume connected to an ÄKTA FPLC sys-
tem (GE Healthcare). The separation was done at a 0.5
ml min–1 flow rate using PBS as the eluent while the
chromatogram was recorded using absorbance at
280 nm and 2 ml fractions were collected. After separa-
tion, the indicated fractions were pooled and concen-
trated using ultracentrifugation as described above.
Flow cytometer analyses of labelled EVs
For the identification and quantification of EVs, samples
were double-stained with AnV (-PE or FITC conjugated,
Biolegend) and an antibody against one of the following
cell surface markers: PE-CD42a (platelet, BD Pharmingen,
Franklin Lakes, NJ, USA), FITC-CD31 (endothelial cells,
Biolegend), PE-CD69 (early activated cells, Biolegend) PE-
CD105 (epithelial/endothelial cells, Biolegend), PE-CD3
(T-cells, BD Pharmingen) and PE-CD14 (monocytes, BD
Pharmingen). Then 25 μl EVs aliquots were incubated
with a staining cocktail containing of 5 µl AnV (as
instructed in the manufacturers protocol) and 1 µg ml–1
of one of the indicated cell surface markers) for 30 min at
RT in dark. Following staining, EVs were washed by
ultracentrifugation and then dissolved in 500 µl of 1× BB,
particles were counted on a FACS Calibur (Becton
Dickinson) flow cytometer using a 60 s acquisition time
at a “medium-flow” setting and data evaluation was per-
formed using the CellQuest Pro Software (Becton
Dickinson) . Of note, in order to gate-out air bubbles,
electrical noise and contaminating particles, a very strin-
gent FSC-SSC gating strategy was used as indicated by the
“EV-associated particle gate” (Supplementary Figure 2). In
addition, to gate out particles >1 µm, latex beads (Sigma
LB-11, St. Louis, MO, USA) with 1.1 µm diameter were
used to define our EV associated gate. The optimised
acquisition settings were controlled weekly. In some
experiments, data acquisition was performed on an
Accuri C6 Flow cytometer with similar results to those
obtained using the FACS Calibur.
Calculation of EV number in one ml plasma
Our initial optimisation studies were performed with
standard calibration beads of known concentration
(1 × 107 beads ml–1, Sigma LB-11, 1.1 µm in dia-
meter). We acquired the # of events (@ 1 min) and
determined the volume utilised for that run. After
verification, we acquired AnV positive EVs and multi-
plied with the dilution factor to determine the # of
EVs ml–1 plasma.
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Binding and uptake of EVs by PBMCs
Purified EVs were stained with the lipophilic cell tracers
of CM-Dil (for confocal studies) and SP-DiOC (for bind-
ing and uptake studies) at 1 µM concentration by incu-
bating for 30 min at 37°C and then washed two times in
35 ml PBS and centrifuged at 100,000g for 1 h. As a
negative control, 1 µM dye, both for CM-Dil and SP-
DiOC, was incubated in the absence of EVs and then
washed twice. Following re-suspension in 200 µl of endo-
toxin-free PBS, labelled EVs were incubated with
2 × 106 ml–1 PBMCs at the at 1:2 cell:EV ratio. For
binding and uptake studies, cells were incubated with
SP-DiOC labelled EVs for various time points and cells
were analysed by Accuri C6 flow cytometer. For confocal
microscopy studies, cells were incubated on cover slips
with CM-Dil labelled EVs for 8 h (at 1:2 cell:EV ratio),
washed, fixed and studied using a Zeiss LSM5 (Carl Zeiss,
Oberkochen, Germany) confocal microscope.
Human ELISA studies
EVs from active BD, inactive BD and healthy subjects were
incubated with healthy PBMCs and autologous PBMCs
(1.25 × 106 per ml) for 12 h at a ratio of 1:2 (Cell:EV) in
96-well flat bottom culture plates. In some experiments,
healthy EVsweremixedwith recombinant LL37 (AnaSpec,
Freemont, CA, USA) overnight and incubated with auto-
logous PBMCs ifor 12h. In neutralization studies anti-LL37
mAb (HyCult Biotech, Uden,Netherlands) were incubated
with EV treated PBMCs at indicated concentrations. LPS
(5 µg ml–1) and PGN (5 µg ml–1) were used as positive
controls throughout these assays. Culture supernatants
were collected and IL6 production was determined by
ELISA.[34] The concentration of LL37 from plasma and
EV samples was measured by a human LL37 ELISA kit
(HyCult Biotech), according to the manufacturer’s
protocol.
Intracellular cytokine staining
Healthy EVs with or without LL37 were used to stimulate
healthy PBMCs for determining IP10, IL1β and IFNα
positive cells. Healthy PBMCs were stimulated with EV
or EV/LL37 complex for 6 h and 16 h in the presence of
Brefeldin-A (5 µg ml–1, Biolegend, Cat#420601) for IL1β
and IP10 analysis, respectively. Of note, Brefeldin-A was
added at t = 0 and t = 6th hour of incubation for IL1β
and for IP10, respectively. The cells were then fixed with
Fix & Perm Medium A (Invitrogen, Cat# GAS001S100).
Cells were first stained with CD14-PE (Biolegend,
Cat#325606) and then to detect the level of intracellular
IL1β or IP10 were stained wither with IL1β-FITC (e-
Biosciences, Cat# 12-7018-81) or IP10-Biotin (BD, Cat#
555048) then SA-FITC (Biolegend, Cat# 405202) in the
presence of saponin (0.1%).
IFNα secreting cells were analysed with Miltenyi
Biotech’s (San Diego, CA, USA) IFNα Secretion Assay
and Detection Kit (PE-labelled, Miltenyi, Cat#
130-094-161) from PBMCs in accordance with kit
instructions. Additionally, in order to identify IFNα
secreting pDCs, cells were stained with BDCA-2-FITC
(Biolegend, Cat# 354208) and then analysed by BD
Accuri C6 flow cytometer.
Statistical analysis
All statistical data analyses were carried out using the
Sigma Stat 3.5 (Systat Software Inc., London, UK). In
order to assess significance between active BD, inactive
BD and healthy groups, one-way ANOVA test was used,
while Student’s t-test was applied to analyse significance
between sub-groups of active BD vs. inactive BD.
p-values ≤0.05 were set to be statistically significant.
Results
Characterisation of EVs from blood plasma
We collected EVs following either ultracentrifugation or
sucrose cushion and conducted Western blotting ana-
lyses. The exosome marker proteins Alix, and Grp94
were detected in EVs purified from plasma
(Supplementary Figure 1(a)). Furthermore, via bead-
based flow cytometric analysis, we demonstrated that
EVs express cardinal markers such as CD9 and CD63
(Supplementary Figure 1(b)). Moreover, isolated EVs
were subjected to dynamic light scattering analyses to
determine the size distribution. DLS investigation
revealed that the size of the purified EVs from healthy
or BD patient plasmas following ultracentrifugation or
sucrose cushion were in the expected size range (ranging
between ~30 and 1000 nm, Supplementary Figure 1(c)).
BD patients have elevated circulating EV numbers
To assess whether plasma EV concentrations correlated
with BD severity, EV numbers in plasma of 72 BD patients
(active; n = 35, inactive; n = 37) and 22 healthy controls
were determined by flow cytometry. Results presented in
Figure 1 show that total plasma EV concentrations (num-
ber of EV ml–1 plasma) were significantly higher in active
BD (3.9 ± 0.77 × 105) and inactive BD (2.05 ± 0.46 × 105)
compared to healthy plasma EVs (0.78 ± 0.25 × 105,
p < 0.001, active vs. healthy, and inactive vs. healthy).
Total EV numbers in active BD were consistently higher
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than the inactive BD group (p < 0.01) and this increase
(1.75–2.2-fold) was valid in all patient sub-groups, suggest-
ing that elevated EV levels was a common feature of active
disease and was not dependent on organ involvement
(Figure 1(a), p < 0.01 for all tested sub-groups).
Platelet derived EVs constitute the majority of
circulating EVs in BD plasma
EVs are believed to be secreted from multiple cell
types, including platelets, endothelial cells, monocytes,
and T cells. However, contribution of each population
to the circulating EV pool can vary depending on
disease activity. To elucidate whether source of EVs
varied with respect to BD severity, isolated particles
from healthy (n = 22), inactive (n = 35) and active
BD patients (n = 37) were stained with different cell
specific markers and their relative ratios were con-
firmed by flow cytometry. The gating strategy for
flow cytometric analysis and representative dot-plots
of individual plasma EV staining are detailed in
Supplementary Figure 2 and Supplementary Figure 3.
Flow cytometric analysis of stained EV populations
revealed that platelets were the most common source
of EV population in all groups (Figure 1(b)). Platelet-
derived EV percentages correlated with disease state
and were found to be significantly elevated in BD
patients (52.6 ± 4.5% and 65.4 ± 3.8%, inactive and
active BD, respectively) when compared to healthy
controls (41.5 ± 4.3%, p < 0.001 for all comparisons).
Similarly, significant increases were found for EVs
derived from T cells (Figure 1(b), 1.49 ± 0.36,
4.14 ± 0.77 and 5.25 ± 1.24% for healthy, inactive and
active BD, respectively; p < 0.001) and monocytes
(Figure 1(b), 1.39 ± 0.32, 3.27 ± 0.42 and 5.7 ± 0.56%
for healthy, inactive and active BD, respectively;
p < 0.001). In contrast, endothelial and/or epithelial
derived EVs in BD plasma were lower than those
observed in healthy controls (p < 0.001 for all
comparisons).
EVs are internalised by PBMCs triggering IL6
secretion
The underlying reasons for the heightened and sus-
tained immune activation in BD patients remain elu-
sive. We established that circulating EV concentrations
are elevated, especially in active BD plasmas. We next
attempted to explore the role of heightened EV con-
centration as a culprit in sustained immune activation
in BD patients. To test this possibility, we investigated
the EV internalisation using fluorescently labelled
extracellular vesicles. For this, lipophilic CM-DiI dye
labelled EVs were incubated with healthy PBMCs and
their associations were analysed by confocal micro-
scopy (Figure 2(a)). Photomicrographs revealed that
BD EVs were effectively associated with immune cells
(Figure 2(a)). This association is not mediated by non-
specific binding of EVs to PBMCs because there was no
cellular staining following incubation of EVs with cells
at 4°C. The signal was EV specific as there was no non-
specific dye binding to cells upon incubating centri-
fuged CM-DiI dye pellet with cells (Figure 2(a), middle
and lower panels). We next attempted to explore
Figure 1. Differential levels and cellular origin of EVs in BD
plasma. (a) Plasma EVs were purified and stained with AnV-FITC
as described in the Materials and Methods section. Number of
EVs per ml plasma was calculated following flow analyses of
AnV positive EV signals. Numbers in parentheses represent
number of subjects studied. (b) EVs were stained with corre-
sponding cell type specific surface markers as well as AnV. Data
are represented as the mean percentage of AnV positive EVs
derived from each cell type ± SD for all samples. Individual dot-
plots were used to calculate CD3 (T-cells), CD14 (monocytes),
CD42a (platelets), CD31 (endothelial cells) and CD105 (epithe-
lial cells) derived EV ratios over total EVs from healthy (n = 22),
inactive BD (n = 37) and active BD (n = 35) donors. *p < 0.01
and **p < 0.001 for comparison groups based on Student’s
t-test analyses of healthy vs. inactive BD, healthy vs. active BD
and inactive BD vs. active BD. NS indicates not significant.
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whether active BD EVs were capable of triggering an
immune response. We incubated EVs isolated from
healthy, inactive or active BD with healthy PBMCs
for 12 h and determined EV-induced cytokine secre-
tion from culture supernatants. Results revealed that
autologous and allogeneic healthy plasma-derived EVs
triggered lower but detectable levels of IL6 production
from healthy PBMC (Figure 2(b), 49.9 ± 19.0 and
116.1 ± 35.4 ng ml–1, respectively). In contrast, inactive
and active BD patients’ EVs triggered 2-fold and 3.3-
Figure 2. BD EV binding and IL6 secretion by PBMCs. (a) Confocal images showing interaction of EVs following 8 h of incubation
with PBMCs. The upper panel shows incubation at 37°C. The middle panel is the interaction of stained EVs with cells at 4°C. The
lower panel is the negative control which indicates there is no interaction of the precipitated dye following ultracentrifugation. The
left panel represents CM-DiI positive signal; the middle panel represents DIC images of the cells and the right panel shows merged
images (scale bar = 20 µm). (b) Healthy PBMCs were incubated with autologous or allogeneic EVs at a cell:EV ratio of 1:2 for 12 h.
IL6 production was assessed from the culture supernatants by ELISA. (autolog EV; autologous EVs from healthy donor; allo EV;
allogeneic EVs from healthy donor; iBD EV; inactive BD EVs and aBD EV; active BD EVs). n = 12 samples, **p < 0.001 for all
comparisons.
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fold more IL6 (Figure 2(b), 235.1 ± 38.0 and
384.9 ± 51.3 ng ml–1, respectively) when compared to
allogeneic healthy EVs (p < 0.001 for all comparisons).
These findings demonstrate that EVs can interact with
and are internalised by human PBMCs and this inter-
action leads to a more pronounced IL6 production
when EVs were of BD origin.
Active BD patient plasma LL37 levels are elevated
and majority of LL37 is associated with EVs
After establishing that circulating EVs are elevated in
active BD plasma and are mediating exaggerated cyto-
kine secretion from PBMCs, we embarked on identify-
ing the factor(s) that might contribute to BD EV-
associated immune activation. For this, we analysed
the plasma levels of LL37, an anti-microbial peptide
associated with the pathogenesis of several autoim-
mune/inflammatory diseases, including psoriasis, sys-
temic lupus erythematosus, rheumatoid arthritis and
atherosclerosis.[35] LL37 concentrations were found
to be 39 ± 8, 80 ± 11 and 207 ± 16 ng ml–1 in healthy,
inactive and active BD plasma samples, respectively
(Figure 3(a)), representing a 2-fold (inactive) and 5-
fold (active) increase.
Considering that LL37 is a cationic peptide and EVs
are enriched in negatively charged phospholipids such
as phosphatidyl serine [36], we next analysed the pos-
sibility of EV/LL37 interaction and determined the
levels of LL37 in EV-depleted plasma and in the EV
fraction following ultracentrifugation of donor plas-
mas. Strikingly, ~2/3 of LL37 was found to be asso-
ciated with EVs in active BD (Figure 3(b)).
To further purify EV preparations, we applied EV
pellets (following ultracentrifugation) onto sucrose
cushion. From this fraction, LL37 detection by ELISA
was performed. As seen in Figure 3(c), LL37 level of
EVs isolated from active BD plasma were significantly
higher than inactive BD EVs or healthy plasma EVs
(9.8 ± 3; 29.1 ± 8.6, and 70.6 ± 11.2 ng ml–1 LL37 in
healthy, inactive BD and active BD EVs, respectively,
n = 12 for each samples, p < 0.001). Furthermore,
consistent with previous findings provided in Figure 2
(b), active BD EVs induced significantly higher IL6
secretion than inactive BD EVs and healthy EVs
(Figure 3(c), right panel, p < 0.001). Collectively,
Figure 3. Elevated levels of antimicrobial peptide LL37 are mostly associated with EVs in BD patients. (a) LL37 concentrations
(ng ml–1) in EV depleted plasma, EV fraction and in plasma of BD patients and control healthy subjects were assessed by LL37 ELISA
kit. (b) LL37 levels of EVs and IL6 induction capacities of EVs (alloEV-healthy EVs; iEV-inactive BD EVs and aEV-active BD EVs) from
healthy PBMCs after sucrose cushion purification (n = 12 for all samples and **p ≤ 0.001 for all comparisons).
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these findings implied that EVs are associated with
LL37 and are capable of inducing IL6 secretion from
healthy PBMCs (Figure 3(c)).
In order to further rule out contribution of unasso-
ciated LL37 aggregates to observed immune activation,
we additionally subjected plasma from healthy and active
BD patients to size exclusion chromatography purifica-
tion (SEC) (Supplementary Figure 4(a)). The SEC frac-
tions were then analysed for expression of cardinal EV
markers via the bead method and each fraction was
analysed by flow cytometer (Supplementary Figure 4
(b)). As expected, EV markers such as CD9 and CD63
were highly abundant only in fraction #1 (>2–2.5-fold
more marker expression) coinciding only to the EV frac-
tion, compared to other fractions as expected, suggesting
the presence of EVs in this fraction (Supplementary
Figure 4(b)). Furthermore, LL37 levels of each fraction
was analysed by ELISA and found to be significantly
higher in the SEC fraction #1, thereby coinciding with
the EVs (Supplementary Figure 4(c), SEC Fraction #1:
58.9 ± 7.1; SEC Fraction #2: 5.7 ± 1.9, and SEC Fraction
#3: 21.6 ± 2.7 ng ml–1), Lastly, we checked the IL6 induc-
tion potential of each SEC fraction. Following incubation
of fractions with healthy PBMCs for 12 h in culture, data
revealed that significantly higher levels of IL6 was
obtained only from cell supernatants that was treated
with active BD derived plasma fraction #1 compared to
healthy EV fractions. Furthermore, only fraction #1 of
active BD plasma induced IL6 secretion compared to
fraction #2 and fraction #3 (185.4 ± 30.9 ng ml–1,
28.6 ± 7.5 ng ml–1, and 49.1 ± 14.1 ng ml–1, for SEC
Fraction #1, #2, and #3, respectively) (Supplementary
Figure 4(d), p < 0.001).
LL37 association with EV governs cellular
internalisation and cytokine induction
LL37 was previously shown to interact with and enhance
delivery of nucleic acids to immune cells.[37] To assess
whether a similar mechanism could operate for EVs, SP-
DiOC labelled healthy EVs were either used as such or
mixed with LL37 peptide (endotoxin free) prior to incuba-
tion with healthy donor PBMCs (Figure 4). Binding of EVs
was significantly enhanced when PBMCs were incubated
with LL37 associated EVs. This enhanced binding was
much pronounced when incubation period was extended
to 8 h (Figure 4(a) and Supplementary Figure 5, p < 0.001,
EV vs. EV + LL37 comparison).
Next, to establish whether this enhanced LL37-
mediated cellular internalisation had an impact on sub-
sequent cytokine induction, healthy EVs were mixed
with increasing concentrations of LL37 or its
scrambled-control prior to co-culture with healthy
PBMCs. As seen in Figure 4(b), LL37/EV combination
induced significantly higher IL6 secretion from PBMCs
in a dose dependent manner (p < 0.001). This induction
was specific to LL37 since the scrambled peptide (SCR/
EV) combination did not yield appreciable amounts of
IL6 (Figure 4(b)). Although free LL37 also triggered IL6
release at these doses, EV/LL37 combination triggered
2.2–2.3-fold more IL6 than the free peptide at both
doses (150 and 450 ng, respectively, Figure 4(b)). To
further demonstrate that any contaminating LL37
aggregate together with EVs does not contribute to IL6
production by PBMCs, we conducted an additional
experiment using THP1 cell derived EVs. We isolated
EVs from THP1 cell supernatants that were devoid of
any plasma components and complexed with LL37 as
described earlier and incubated with PBMCs. As done
previously, IL6 production by PBMCs was assessed by
ELISA. As seen in Figure 4(c), EV/LL37 treated PBMCs
secreted more IL6, representing a 2.1-fold higher cyto-
kine production compared to cells that were treated
with free LL37 (Figure 4(c)). Consistently, scrambled
peptide mixed EVs failed to secrete any appreciable
levels of IL6. To further prove that indeed LL37 associa-
tion to EVs regulates cytokine induction by PBMCs,
next, we treated cells with EV/LL37 complex in the
presence and absence of anti-LL37 antibody and
detected IL6 levels from cell supernatants. As seen in
Figure 4(d), in a dose-dependent manner anti-LL37
addition onto LL37-EV treated cells significantly abro-
gated IL6 secretion from PBMCs suggesting that LL37/
EVs regulate IL6 secretion from PBMCs (Figure 4(d)).
Of important note, IL6 secretion capacity of EVs iso-
lated from inactive and active BD patient plasmas sig-
nificantly reduced when increasing doses of anti-LL37
antibody was incubated with healthy PBMCs
(Supplementary Figure 5(b)).
Active BD EVs triggers IFNα from pDC, IL1β and
IP10 from monocytes/macrophages
Our findings implicated that LL37 associated EVs
are capable of inducing elevated immune activation.
To identify the cell types activated by LL37/EV
complexes, healthy donor EVs were mixed with
LL37, (mimicking active BD EVs) and subsequently
incubated with healthy PBMCs. LL37-free and LL37
associated-EV binding profiles in dendritic cell
(DC), macrophage and T-cell populations were
assessed with flow cytometer 1 h after co-incubation
(Figure 5 and Supplementary Figure 5(a)). Results
showed that EV delivery to macrophages, DCs and
to a lesser extent to T-cells were significantly
enhanced in the presence of LL37 (Figure 5(a)).
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Next, EV mediated immune activation by blood per-
ipheral cells were investigated. As expected, healthy EVs
devoid of LL37 failed to induce any detectable IFNα or
IL1β (Figure 5(b), and Supplementary Figure 6).
However, LL37/EV complexes induced >2-fold more
IL1β, and >20-fold more IFNα production from mono-
cytes and plasmacytoid dendritic cells (pDC), respec-
tively. Similarly, IP10 production from monocytes was
Figure 4. LL37 promotes EVs uptake and IL6 induction by immune cells can be suppressed by LL37 antibody. (a) SP-DiOC labelled
healthy EVs or LL37/EV complexes were incubated with healthy PBMCs at 1:2 ratio (cell:EV) for indicated time periods. The line
graph shows the kinetic of EVs association by cells in the presence or absence of LL37. (b) EVs isolated from healthy plasma were
complexed overnight at 4°C either with 150 ng (grey bars) or with 450 ng (black bars) LL37, and then incubated with healthy PBMCs
for 12 h at 1:2 (cell:EV) ratio. IL6 levels were assessed from culture supernatants by ELISA. (c) IL6 induction capacity of EVs isolated
from THP-1 cells that is devoid of any plasma contamination. (d) Dose-dependent suppression of LL37/EV mediated IL6 production
by PBMCs following treatment with anti-LL37 antibody for 12 h in culture. **p < 0.001 for all comparisons.
JOURNAL OF EXTRACELLULAR VESICLES 9
elevated only in response to LL37-EV (Figure 5(c), >2-
fold more IP10 was secreted). Of note, IFNα, IL1β and
IP10 productions from pDC and monocytes were
dependent on LL37-EV complex since treatment of
cells only with LL37 failed to reproduce similar immune
stimulatory activity.
Figure 5. EVs associated with LL37 can be taken up by immune cells and boost IL1β and IP10 from monocytes and IFNα from pDCs.
(a) Cell specific binding of LL37-free and LL37-associated EVs. SP-DiOC stained EVs were incubated with PBMCs for 1 h and analysed
by flow cytometer following cell-specific surface marker staining. (b) IL1β and IFNα secreting monocytes and pDCs, respectively,
were assessed by intracellular cytokine staining technique. (c) Histogram of IP10 secreting monocytes were shown following
treatment of cells either with EVs or free LL37 and LL37/EV complex.
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When taken together, these findings demonstrated
that (i) LL37 levels, (ii) EVs concentration and (iii) patho-
logical cytokine production are well correlated with dis-
ease severity (Figure 6, R2: 0.9275, and Supplementary
Figure 7(a) and 7(b)).
Collectively, our findings established that active BD
patient plasmas contain elevated numbers of circulating
EVs, and majority of LL37 does not co-exist in the EV
pellet as a contaminating aggregate but are physically
associated with LL37. The EV-LL37 complex drives EVs
specifically and efficiently to immune cells, probably
inducing robust and sustained immune activation.
Discussion
EVs have recently been implicated as novel extracellu-
lar mediators of distant intercellular communication.
[11] Since EVs circulate and remain intact in periph-
eral blood, they are capable of transferring labile cargo
to distant targets, thereby altering the physiology of the
recipient cells. This study is the first to demonstrate
that EVs are elevated in the peripheral blood of BD
patients, suggesting their potential involvement in dis-
ease pathogenesis.
Several studies demonstrated that EVs not only pos-
sess bioactive materials on their surface but also harbour
biologically active cargo within their lumen. These
include nucleic acids (both RNA and DNA) or proteins,
such as cytokines, growth factors and cell or tissue spe-
cific antigens. Recently, miRNAs were also reported to be
delivered via these structures.[38–40] EVs are considered
to have important functions in establishment of home-
ostasis in health and could play potentially detrimental
roles during disease states.[41,42] Data presented herein
are in support of these observations and extend our
current knowledge of EV-disease associations.
Several concerns could be raised during working
with plasma in an EV related study, such as contam-
ination of EVs during the isolation step with several
other unrelated proteins or protein aggregates that
ultimately overshadow the anticipated results.
Importantly, the presence of negatively charged apoli-
poproteins in EV pellets as a contaminant could facil-
itate association of cationic plasma LL37 with
apolipoproteins. However, according to two studies,
this association abrogates LL37 inherent immune
related activity.[43,44] Since we purified EVs also on
a sucrose cushion, we consider it unlikely that apoli-
poprotein mediated LL37 complexes contributed to the
activities observed by EV-LL37.
Our findings could be of clinical interest for several
reasons. First, plasma EV numbers were found to be
elevated in BD patients, which correlated with disease
severity (higher EV numbers in active BD patients). It
is conceivable that a plasma EV number-based stratifi-
cation of BD could more precisely identify inactive and
active disease states and could aid in pharmacological
management of this disease.
Second, although LL37 is a cationic anti-microbial
peptide generally known to be secreted during pathogenic
insult,[45–47] the data presented here demonstrate that
plasma LL37 levels are elevated in BD. As in the case of
EVs, this information could be of value to follow patient
responses to treatment. Of interest, the only published
data that investigated a role of LL37 in BD revealed
elevated LL37 levels in saliva of BD patients which corre-
lated with the number of monthly oral ulcers.[48]
Consistent with this observation, our results also revealed
a correlation between LL37 levels and disease severity. Of
note, LL37 levels were reported to be higher during sterile
inflammation.[49] In addition, this cationic peptide was
demonstrated to contribute to IL-1β, IL6, MCP-1 and
MCP-3 production.[50] In this context, our results also
established a link between elevated LL37 levels and
enhanced cytokine production.
Third, to our knowledge this paper is the first to
show that LL37 can interact with EVs, enhancing their
cellular delivery and immune stimulatory activity. As
stated before, EVs are known carriers of self-nucleic
acids. It is conceivable that LL37-mediated enhanced
EV delivery to immune cells could activate several
endosomal and/or cytosolic RNA and DNA-dependent
nucleic acid sensors, including TLR7, TLR9, RIG-I,
MDA-5, cGAS or AIM-2, leading to production of
Figure 6. Disease activity strongly correlates with LL37 and IL6
concentrations. Healthy, inactive and active BD patient EVs
were analysed for LL37 association levels and subsequent IL6
production by healthy PBMCs. The correlation plot was pre-
pared from these two independent data to determine the
correlation coefficient between disease states IL6 secretion
and LL37 levels. R2 = coefficient of correlation (n = 12 for all
sample plasmas).
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BD-associated cytokines (i.e. IL6, IL-1β and IFNα),
contributing to disease severity. Supporting this view,
it was shown that high levels of LL37 present in psor-
iatic skin formed complexes with genomic DNA liber-
ated from dying cells, and enhanced DNA delivery to
pDCs, triggering a TLR9-mediated interferon alpha
response in psoriatic patients.[51]
The anionic charge of EVs provides a surface con-
venient for complexing with LL37. Our findings imply
that LL37-mediated enhanced delivery of circulating
EVs to immune cells contributes to sustaining and
exacerbating immune activation in active BD.
Therefore, targeting this peptide could be of therapeu-
tic value in the management of this complex disease.
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